Theophile Bigirumurame

Generating author description...

All published works

Action	Title	Year	Authors
+	Master protocols in Low-and-Middle income countries: A review of current use, limitations and opportunities for precision medicine	2024	Luke Ouma Sarah Al-Ashmori Samuel K Sarkodie Lou E. Whitehead Ann Breeze Konkoth Shaun Hiu Theophile Bigirumurame Dorcas Kareithi Jingky Lozano-Kühne Marzieh Shahmandi
+ PDF Chat	Utilising high-dimensional data in randomised clinical trials: A review of methods and practice	2023	Svetlana Cherlin Theophile Bigirumurame Michael J. Grayling Jérémie Nsengimana Luke Ouma Aida Santaolalla Fang Wan S. Faye Williamson James Wason
+ PDF Chat	Current practices in studies applying the target trial emulation framework: a protocol for a systematic review	2023	Theophile Bigirumurame Shaun Hiu M. Dawn Teare James Wason Andrew Bryant Matthew Breckons
+	Utilising high-dimensional data in randomised clinical trials: a review of methods and practice	2023	Svetlana Cherlin Theophile Bigirumurame Michael J. Grayling Jérémie Nsengimana Luke Ouma Aida Santaolalla Fang Wan S. Faye Williamson James Wason
+	Sequential multiple assignment randomized trial studies should report all key components: a systematic review	2021	Theophile Bigirumurame Germaine Uwimpuhwe James Wason
+ PDF Chat	Innovative trial approaches in immune-mediated inflammatory diseases: current use and future potential	2021	Michael J. Grayling Theophile Bigirumurame Svetlana Cherlin Luke Ouma Haiyan Zheng James Wason
+ PDF Chat	Can testing clinical significance reduce false positive rates in randomized controlled trials? A snap review	2017	Theophile Bigirumurame Adetayo Kasim
+	Applied Surrogate Endpoint Evaluation Methods with SAS and R	2016	Ariel Alonso Theophile Bigirumurame Tomasz Burzykowski Marc Buyse Geert Molenberghs Leacky Muchene Nolen Joy Perualila Ziv Shkedy Wim Van der Elst
+	The R Package Surrogate	2016	Ariel Alonso Theophile Bigirumurame Tomasz Burzykowski Marc Buyse Geert Molenberghs Leacky Muchene Nolen Joy Perualila Ziv Shkedy Wim Van der Elst

Common Coauthors

Coauthor	Papers Together
James Wason	6
Luke Ouma	4
Michael J. Grayling	3
Svetlana Cherlin	3
Ziv Shkedy	2
Marc Buyse	2
Ariel Alonso	2
Fang Wan	2
Nolen Joy Perualila	2
Jérémie Nsengimana	2
Geert Molenberghs	2
Aida Santaolalla	2
Tomasz Burzykowski	2
Wim Van der Elst	2
S. Faye Williamson	2
Shaun Hiu	2
Leacky Muchene	2
Ann Breeze Konkoth	1
Adetayo Kasim	1
Lou E. Whitehead	1
Matthew Breckons	1
Germaine Uwimpuhwe	1
M. Dawn Teare	1
Haiyan Zheng	1
Andrew Bryant	1
Samuel K Sarkodie	1
Marzieh Shahmandi	1
Dorcas Kareithi	1
Jingky Lozano-Kühne	1
Sarah Al-Ashmori	1

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+	Statistical Methods for Dynamic Treatment Regimes	2013	Bibhas Chakraborty Erica E. M. Moodie	2
+	Developing a predictive signature for two trial endpoints using the cross-validated risk scores method	2020	Svetlana Cherlin James Wason	2
+ PDF Chat	A "SMART" Design for Building Individualized Treatment Sequences	2012	Huitian Lei Inbal Nahum‐Shani Kevin G. Lynch David W. Oslin Susan A. Murphy	2
+ PDF Chat	A SMART data analysis method for constructing adaptive treatment strategies for substance use disorders	2016	Inbal Nahum‐Shani Ashkan Ertefaie Xi Lu Kevin G. Lynch James R. McKay David W. Oslin Daniel Almirall	2
+ PDF Chat	Two‐stage penalized regression screening to detect biomarker–treatment interactions in randomized clinical trials	2021	Jixiong Wang Ashish Patel James Wason Paul J. Newcombe	2
+ PDF Chat	Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available: Table 1.	2016	Miguel A. Hernán James M. Robins	2
+ PDF Chat	Developing and testing high‐efficacy patient subgroups within a clinical trial using risk scores	2020	Svetlana Cherlin James Wason	2
+ PDF Chat	The Cross-Validated Adaptive Signature Design	2010	Boris Freidlin Wenyu Jiang Richard Simon	2
+ PDF Chat	Developing and Validating Continuous Genomic Signatures in Randomized Clinical Trials for Predictive Medicine	2012	Shigeyuki Matsui Richard Simon Pingping Qu John D. Shaughnessy Bart Barlogie John Crowley	2
+	A gate-keeping test for selecting adaptive interventions under general designs of sequential multiple assignment randomized trials	2019	Xiaobo Zhong Bin Cheng Min Qian Ying Kuen Cheung	2
+ PDF Chat	Q-learning: A data analysis method for constructing adaptive interventions.	2012	Inbal Nahum‐Shani Min Qian Daniel Almirall William E. Pelham Beth Gnagy Gregory A. Fabiano James G. Waxmonsky Jihnhee Yu Susan A. Murphy	2
+ PDF Chat	Adaptive Treatment Strategies in Chronic Disease	2007	Philip W. Lavori Ree Dawson	2
+ PDF Chat	Subgroup identification from randomized clinical trial data	2011	Jared C. Foster Jeremy M. G. Taylor Stephen J. Ruberg	2
+ PDF Chat	Adaptive Signature Design: An Adaptive Clinical Trial Design for Generating and Prospectively Testing A Gene Expression Signature for Sensitive Patients	2005	Boris Freidlin Richard Simon	2
+ PDF Chat	Adaptive designs in clinical trials: why use them, and how to run and report them	2018	Philip Pallmann Alun Bedding Babak Choodari‐Oskooei Munyaradzi Dimairo Laura Flight Lisa V. Hampson Jane Holmes Adrian Mander Lang’o Odondi Matthew R. Sydes	2
+	Avoidable flaws in observational analyses: an application to statins and cancer	2019	Barbra A. Dickerman Xabier García‐Albéniz Roger Logan Spiros Denaxas Miguel A. Hernán	2
+ PDF Chat	Estimation of optimal dynamic treatment regimes	2014	Ying‐Qi Zhao Eric B. Laber	1
+	The CONSORT Statement: Revised Recommendations for Improving the Quality of Reports of Parallel-Group Randomized Trials	2001	David Moher Kenneth F. Schulz Douglas G. Altman	1
+	When to Start Treatment? A Systematic Approach to the Comparison of Dynamic Regimes Using Observational Data	2010	Lauren E. Cain James M. Robins Émilie Lanoy Roger Logan Dominique Costagliola Miguel A. Hernán	1
+ PDF Chat	Reporting of sample size calculation in randomised controlled trials: review	2009	Pierre‐Emmanuel Charles Bruno Giraudeau Agnès Dechartres Gabriel Baron Philippe Ravaud	1
+ PDF Chat	On Estimation of Optimal Treatment Regimes for Maximizing<i>t</i>-Year Survival Probability	2016	Runchao Jiang Wenbin Lu Rui Song Marie Davidian	1
+ PDF Chat	A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results	2015	Tessa Kennedy‐Martin Sarah L. Hulin-Curtis Douglas E. Faries Susan Robinson Joseph A. Johnston	1
+ PDF Chat	Effectively Selecting a Target Population for a Future Comparative Study	2013	Lihui Zhao Lü Tian Tianxi Cai Brian Claggett L. J. Wei	1
+ PDF Chat	Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses	2016	Miguel A. Hernán Brian C. Sauer Sonia Hernández–Dı́az Robert W. Platt Ian Shrier	1
+	Demystifying Optimal Dynamic Treatment Regimes	2007	Erica E. M. Moodie Thomas S. Richardson David A. Stephens	1
+ PDF Chat	An investigation of the impact of futility analysis in publicly funded trials	2014	Benjamin Sully Steven A. Julious Jon Nicholl	1
+	Estimating causal effects of treatments in randomized and nonrandomized studies.	1974	Donald B. Rubin	1
+ PDF Chat	Dynamic Treatment Regimes	2013	Bibhas Chakraborty Susan A. Murphy	1
+	Regression Shrinkage and Selection Via the Lasso	1996	Robert Tibshirani	1
+	The number of subjects per variable required in linear regression analyses	2015	Peter C. Austin Ewout W. Steyerberg	1
+	Binary regression with continuous outcomes	1995	Samy Suissa Lucie Blais	1
+	Ridge Estimators in Logistic Regression	1992	Saskia le Cessie Hans C. van Houwelingen	1
+ PDF Chat	Optimal two-stage designs for phase II clinical trials	1989	Richard Simon	1
+ PDF Chat	Effect Identification in Comparative Effectiveness Research	2013	Michael Oakes	1
+ PDF Chat	Learning Interactions via Hierarchical Group-Lasso Regularization	2014	Michael Lim Trevor Hastie	1
+	Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes	2010	Linda E. Lévesque J. A Hanley Abbas Kezouh Samy Suissa	1
+ PDF Chat	Using continuous data on tumour measurements to improve inference in phase II cancer studies	2013	James Wason Shaun R. Seaman	1
+ PDF Chat	Cross-validation pitfalls when selecting and assessing regression and classification models	2014	Damjan Krstajić Ljubomir Buturović David E. Leahy Simon Thomas	1
+ PDF Chat	Experimental design and primary data analysis methods for comparing adaptive interventions.	2012	Inbal Nahum‐Shani Min Qian Daniel Almirall William E. Pelham Beth Gnagy Gregory A. Fabiano James G. Waxmonsky Jihnhee Yu Susan A. Murphy	1
+ PDF Chat	Statistical challenges of high-dimensional data	2009	Iain M. Johnstone D. M. Titterington	1
+ PDF Chat	Development and validation of biomarker classifiers for treatment selection	2007	Richard Simon	1
+ PDF Chat	Boosting power for clinical trials using classifiers based on multiple biomarkers	2010	Omid Kohannim Xue Hua Derrek P. Hibar Suh Lee Yi‐Yu Chou Arthur W. Toga Clifford R. Jack Michael W. Weiner Paul M. Thompson	1
+ PDF Chat	A small n sequential multiple assignment randomized trial design for use in rare disease research	2015	Roy Tamura Jeffrey P. Krischer Christian Pagnoux Robert G. Micheletti Peter C. Grayson Yeh‐Fong Chen Peter A. Merkel	1
+	Biomarker based clinical trial design.	2014	Richard Simon	1
+ PDF Chat	Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review	2016	Miranta Antoniou Andrea Jorgensen Ruwanthi Kolamunnage‐Dona	1
+ PDF Chat	Biomarker-Adaptive Threshold Design: A Procedure for Evaluating Treatment With Possible Biomarker-Defined Subset Effect	2007	Wei Jiang Boris Freidlin Richard H. Simon	1
+ PDF Chat	SMART designs in cancer research: Past, present, and future	2014	Kelley M. Kidwell	1
+	A SMART design to optimize treatment strategies for patient and family caregiver outcomes	2016	Mi‐Kyung Song Annette DeVito Dabbs Sandra E. Ward	1
+	Reducing sample sizes in two-stage phase II cancer trials by using continuous tumour shrinkage end-points	2011	James Wason Adrian Mander Tim Eisen	1
+ PDF Chat	The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials	2001	David Moher Kenneth F. Schulz Douglas G. Altman	1